Results of an early safety analysis of a study of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer.
Linda R DuskaJennifer M ScaliciSarah M TemkinJulie K SchwarzErin K CraneKatherine M MoxleyChad A HamiltonStephanie L WethingtonGina R PetroniNikole E VarhegyiSheena H CliftTimothy N J BullockTimothy N ShowalterPublished in: Cancer (2020)
Pembrolizumab is a humanized antibody against programmed cell death protein 1 that is used in cancer immunotherapy. Preliminary data suggest that pembrolizumab can be safely combined with chemotherapy and pelvic radiation in the treatment of locally advanced cervical cancer. Future studies of the addition of immunotherapy to traditional chemoradiation are planned to determine the best way to deliver the treatment and whether any improvement is seen with the addition of immunotherapy to traditional therapy.
Keyphrases
- locally advanced
- rectal cancer
- neoadjuvant chemotherapy
- squamous cell carcinoma
- phase ii study
- radiation therapy
- advanced non small cell lung cancer
- stem cells
- big data
- electronic health record
- mesenchymal stem cells
- artificial intelligence
- deep learning
- current status
- radiation induced
- data analysis
- replacement therapy
- smoking cessation
- monoclonal antibody
- open label